Skip to main content
. 2022 Feb 24;39(4):1810–1831. doi: 10.1007/s12325-022-02068-7

Fig. 4.

Fig. 4

Estimated proportion of patients with NEDA-3 after 1 or 2 years of DRF treatment in EVOLVE-MS-1. DRF diroximel fumarate, GA glatiramer acetate, IFN interferon, NEDA-3 no evidence of disease activity-3